These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1829079)

  • 1. A review of the safety profile of teicoplanin.
    Davey PG; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():69-73. PubMed ID: 1829079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of teicoplanin and vancomycin.
    Wilson AP
    Int J Antimicrob Agents; 1998 May; 10(2):143-52. PubMed ID: 9716291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.
    Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of teicoplanin and vancomycin.
    Wood MJ
    J Chemother; 2000 Nov; 12 Suppl 5():21-5. PubMed ID: 11131960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin in perspective. A critical comparison with vancomycin.
    Janknegt R
    Pharm Weekbl Sci; 1991 Aug; 13(4):153-60. PubMed ID: 1834985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teicoplanin administration in patients experiencing reactions to vancomycin.
    Smith SR; Cheesbrough JS; Makris M; Davies JM
    J Antimicrob Chemother; 1989 May; 23(5):810-2. PubMed ID: 2527221
    [No Abstract]   [Full Text] [Related]  

  • 7. IgE-mediated reaction to vancomycin and teicoplanin after treatment with vancomycin.
    Knudsen JD; Pedersen M
    Scand J Infect Dis; 1992; 24(3):395-6. PubMed ID: 1380722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergic cross-reactivity of teicoplanin and vancomycin.
    McElrath MJ; Goldberg D; Neu HC
    Lancet; 1986 Jan; 1(8471):47. PubMed ID: 2867290
    [No Abstract]   [Full Text] [Related]  

  • 9. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
    Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
    J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teicoplanin for patients allergic to vancomycin.
    Schlemmer B; Falkman H; Boudjadja A; Jacob L; Le Gall JR
    N Engl J Med; 1988 Apr; 318(17):1127-8. PubMed ID: 2965303
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
    Svetitsky S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylactoid reactions to glycopeptide antibiotics.
    Polk RE
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():17-29. PubMed ID: 1711520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
    Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin versus vancomycin for proven or suspected infection.
    Cavalcanti AB; Goncalves AR; Almeida CS; Bugano DD; Silva E
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007022. PubMed ID: 20556772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P; Aoun M; Meunier F
    Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin and teicoplanin: something old, something new.
    Phillips G; Golledge CL
    Med J Aust; 1992 Jan; 156(1):53-7. PubMed ID: 1531153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.
    Rybak MJ; Bailey EM; Warbasse LH
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1204-7. PubMed ID: 1384423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors.
    Kim BK; Kim JH; Sohn KH; Kim JY; Chang YS; Kim SH
    Korean J Intern Med; 2020 May; 35(3):714-722. PubMed ID: 31722513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.